INOVIO Pharmaceuticals ($INO): What Does the October 30 PDUFA Actually Turn On?

21 Bull, base and bear scenarios

These are reading frames, not forecasts, and none of them is a recommendation. Each is written so that a reader can say which document would confirm or break it.

What the three have in common is the date. Unlike most files, this one resolves on a calendar day rather than over quarters, and the balance sheet was built to reach that day rather than to outlast it.

What Would Falsify This Reading

The reading on this page is that the inspection and process parts of the INO-3107 review are closed, that the open question is a legal and evidentiary one about eligibility for the accelerated approval pathway, and that the balance sheet was sized to reach October 30 rather than to survive comfortably past it. Each of the following would damage that reading, and each is checkable against a document rather than against an opinion.

• The eligibility question turns out to have been settled off the record. The 10-Q says that at the July 2026 informal meeting the FDA did not discuss its preliminary commentary on accelerated approval eligibility, and that the company continues to believe INO-3107 qualifies while conceding the agency may disagree. If an approval arrives on schedule, the correct reading will be that the agency had already moved on from a preliminary comment made in a file acceptance letter, and that this page over-weighted a sentence. If instead the decision turns on eligibility, it was the only thing on the page that mattered.
• A single-arm trial with a safety primary endpoint proves to be enough. RRP-001 enrolled 32 patients at eleven United States sites, was open-label with no control arm, and the registry record lists safety and tolerability as its primary outcome and the change in the number of surgical interventions as a secondary one. Each patient’s own prior year is the comparator. If the FDA approves on that package, a 32-patient uncontrolled study will have supported a licence in a rare disease, which is a real precedent and the opposite of what a sceptical reading of the design would predict.
• PAPZIMEOS turns out not to raise the bar. INOVIO’s own risk factor states that in light of the FDA’s approval of PAPZIMEOS the company anticipates the agency will not approve the INO-3107 BLA under the accelerated pathway unless it demonstrates a clinically meaningful benefit over existing therapies, that product included. If the decision shows the FDA treating the two as addressing different populations or different needs, the competitive argument on this page was too mechanical.
• The company funds itself without heavy dilution. Shares outstanding rose from 68,996,647 at December 31, 2025 to 103,397,518 by August 10, 2026, and 97,706,767 shares sit under outstanding warrants. If the next two quarterly filings show the count broadly stable and the at-the-market programme still dormant, the dilution part of this reading was pessimistic. The direction of travel over the last three years says otherwise, and the stated runway ends in late first quarter 2027.
• The litigation goes nowhere. Carlson v. Inovio alleges materially false and misleading statements about the BLA submission and the FDA’s review timeline; a lead plaintiff was appointed on July 27, 2026, and five derivative complaints follow from the same alleged misstatements. A dismissal at the pleading stage would mean the market’s reaction in February and March 2026 was about disappointment rather than disclosure. Survival past a motion to dismiss would mean the opposite, and that is the document to watch.

None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.

01 Executive answer: the process is finished, the argument is not

On October 30, 2026 the FDA has a Prescription Drug User Fee Act target date for INO-3107, an investigational DNA medicine for the treatment of adults with recurrent respiratory papillomatosis. That date is thirty days after the September 30 close, and it is the central dated event on this file. It is not the only one: the same 10-Q discloses that a seven-day trial in the company’s long-running supply-agreement dispute with VGXI, Inc. and GeneOne Life Science is scheduled to begin on October 13, 2026, seventeen days before the PDUFA date.

What makes the decision unusual is that the parts of a biologics review which normally cause delay are already closed, and the part which normally is not even in question is wide open.

Closed, on the inspection side. The Form 10-Q for the quarter ended June 30, 2026 states that by early August 2026 the FDA had completed its mid- and late-cycle review meetings for the BLA and all scheduled pre-licensure inspections. For a company whose history includes a device platform, contract manufacturing and a plasmid product, finishing inspections without a disclosed observation is the single most reassuring sentence in the filing. It is not the same as saying manufacturing is behind the company: the risk factors disclose that during the testing required for the BLA submission the company identified a manufacturing issue in the single-use administration component of its CELLECTRA 5PSP device, which delayed both the confirmatory trial and the BLA itself; it believes the issue is rectified, and it states that the existing investigational new drug application will have to be updated with the 5PSP device alongside the confirmatory trial protocol, which will be subject to further FDA review.

Open, on eligibility. When the agency accepted the application in December 2025 it noted, in the file acceptance letter itself, a potential review issue: its preliminary conclusion that the company had not provided adequate information to justify eligibility for the accelerated approval pathway. INOVIO requested a meeting in January 2026 to discuss maintaining that eligibility; the FDA agreed and asked the company to complete an assessment aid, which was submitted in February 2026. The informal meeting took place in July 2026. According to the 10-Q, the company presented the totality of the data, the differentiated approach and the rationale for eligibility, discussed the current standard of care and the continuing need for options — and the FDA did not discuss its preliminary commentary on eligibility. The agency said feedback on the confirmatory trial design would be forthcoming.

That last sentence can be read two ways, and this page will not pretend to know which is right. A request for confirmatory trial feedback is what happens when a product is heading for accelerated approval, because such a trial is a condition of it. It is also just a statement that feedback will arrive. The filing supports both readings and settles neither.

Three further facts frame the decision, and all three are in the company’s own documents.

First, the evidence base is one small uncontrolled trial. RRP-001 was an open-label, multi-centre Phase 1/2 study in 32 patients at eleven United States sites. Its registered primary outcome was the percentage of participants with treatment-emergent adverse events; the change in the number of surgical interventions in the year after dosing, compared with the year before, was a secondary outcome. There was no control arm. In the trial, 81.3 per cent of patients — 26 of 32 — had fewer surgical interventions in the year after administration, including 28.1 per cent, nine of 32, who needed none; patients had a median of four surgeries in the prior year, and the median decrease was three, with a 95 per cent confidence interval of −3 to −2.

Second, a competitor is already licensed for the same disease. PAPZIMEOS, a gorilla adenoviral vector-based immunotherapy, was approved for adults with RRP in August 2025. INOVIO’s own risk factors spell out the consequence: in light of that approval, the company anticipates the FDA will not approve the INO-3107 BLA under the accelerated approval pathway unless it demonstrates that INO-3107 provides a clinically meaningful benefit over existing therapies, including PAPZIMEOS. Accelerated approval rests on there being no available therapy or on a benefit over available therapy; the first of those two options closed in August 2025.

Third, there is no stated fallback. The 10-Q says plainly that INOVIO is not currently planning to seek approval for the INO-3107 BLA under the traditional pathway, which could potentially require a Phase 3 trial whose design would need to be agreed with the FDA and which would come at substantial cost.

Against that, the money. Cash, equivalents and short-term investments were $36.7 million at June 30, 2026. Working capital was negative $2,000 and total stockholders’ equity $4.4 million. First-half operating cash use was $39.6 million. With roughly $18.3 million net raised in the July offering, the company says its resources should support planned operations through a potential launch of INO-3107, if approved, and into late first quarter 2027 — and that substantial doubt exists about its ability to continue as a going concern beyond that point. The balance sheet was built to reach the decision, not to absorb a bad one.

So the answer to the question in the title is that October 30 turns on an evidentiary and legal argument rather than on manufacturing or on the data being wrong. The surgical-reduction signal is real and has now been followed for three years. Whether a 32-patient single-arm study, in a disease where another product already holds a full approval, meets the statutory test for accelerated approval is a judgement the FDA has reserved, has flagged once in writing, and has not publicly revisited.

None of that is a view on whether the shares are worth their price, and this page does not offer one.

02 What INO-3107 is, what RRP is, and what the application asks for

Recurrent respiratory papillomatosis is a lifelong rare disease in which papillomas grow in the respiratory tract, caused primarily by human papillomavirus types 6 and 11. The growths are mostly benign but can cause severe and sometimes life-threatening airway obstruction. Their defining feature, and the reason the disease is a treatment problem rather than a surgical one, is that they recur after removal because the underlying infection remains. If the disease reaches the lungs, patients can develop recurrent pneumonia, bronchiectasis and progressive pulmonary failure. In roughly 2 per cent of cases it progresses to squamous cell carcinoma. Other symptoms include hoarseness, difficulty sleeping and swallowing, and chronic coughing, and the disease is usually more severe in children than in adults.

The standard of care is repeated surgery. On the size of the population the company is candid about the weakness of the data: the most widely cited United States epidemiology, published in 1995, estimated approximately 14,000 active cases across adults and juveniles and about 1.8 new adult cases per 100,000 a year. A thirty-year-old prevalence estimate is the anchor for any sizing of this market, and a reader should treat it as such.

INO-3107 is an immunotherapy composed of two plasmids: one encoding the E6 and E7 antigens of HPV-6 and HPV-11, the other encoding human interleukin-12 as an immune activator. It is delivered by intramuscular injection followed by electroporation using one of the company’s CELLECTRA devices — the device is part of the product, which is why device and engineering spending appears in the research line. The pivotal study used the CELLECTRA 2000, which the company describes as the model it primarily uses in earlier-stage trials; the device portfolio for late-stage and potential commercial use is the CELLECTRA 5PSP and 3PSP, and the 10-K states that the 5PSP will be used in the planned confirmatory trial for INO-3107 and that, although it is CE-marked in the European Union, INO-3107 still requires marketing authorisation for the combination product to be commercialised. In the pivotal study patients first had their papillomas surgically removed and then received four doses, one every three weeks.

The mechanism has published support beyond the clinical endpoint. The full safety and efficacy results from RRP-001 were published in Nature Communications in February 2025, having been presented in October 2024, and included immunology data showing that INO-3107 induced antigen-specific T cell responses against HPV-6 and HPV-11, significant clonal T cell expansion in blood including antigen-specific killer T cells, and infiltration of those T cells into airway tissue and papilloma, positively associated with clinical response. In responders, the infiltrating population was predominantly one detectable only after administration of the drug. T cell responses were still observed at week 52, indicating a persistent cellular memory response.

The application asks the FDA to license INO-3107 for the treatment of adults with RRP, under the accelerated approval program. Four points of precision about what that means:

• Adults only. The BLA covers adults, although the pivotal trial enrolled patients with both juvenile-onset disease, defined by a first diagnosis before age twelve, and adult-onset disease, defined by a first diagnosis at twelve or later. The registry record sets a minimum enrolment age of eighteen.
• Accelerated approval, not traditional. That is a deliberate route with its own statutory test, discussed in the next section, and it carries a confirmatory trial obligation.
• Designations do not change the standard. The FDA granted Orphan Drug Designation in July 2020 and Breakthrough Therapy Designation in 2023; the European Commission granted orphan designation; in 2024 INO-3107 was designated an innovative medicine under the United Kingdom’s Innovative Licensing and Access Pathway, and the European Medicines Agency’s Committee for Advanced Therapies certified the quality and non-clinical data as complying with the standards that would be used for a European marketing authorisation. None of that lowers the bar for approval. The company requested a priority review, which is typically six months; the FDA granted a standard ten-month review instead.
• No price, and no European or Japanese application. No list price or wholesale acquisition cost for INO-3107 appears in the filings reviewed for this page, and no marketing application outside the United States is disclosed.

Form 10-K for the year ended December 31, 2025

03 The accelerated approval question, which is the whole file

Everything else on this page is context for this section. It is worth setting out the mechanism precisely, because the argument is technical and the company’s disclosure about it is unusually explicit.

That paragraph is the most important disclosure in the filing, and it is the company’s own, not an interpretation. Note what it concedes and what it does not. It concedes that the easier of the two routes to accelerated approval — no available therapy — closed in August 2025. It does not concede that the harder route is unavailable; the company’s position throughout is that INO-3107 does meet the criteria, by addressing a significant unmet need and providing a meaningful therapeutic benefit over existing treatments.

The documented sequence on eligibility

Why the fallback matters so much

The company states that it is not currently planning to seek approval under the traditional pathway, which could potentially require a Phase 3 trial whose design would need to be agreed with the FDA and which would be at substantial cost. Set that against a balance sheet with $36.7 million at June 30, 2026, a stated runway into late first quarter 2027 and an explicit going-concern doubt beyond it, and the asymmetry is plain: the accelerated pathway is not the preferred route, it is the only route the current financial structure can reach.

Two honest caveats on the other side. The FDA indicated before submission that the Phase 1/2 data could support a filing under the program, which is a meaningful piece of regulatory history rather than wishful thinking. And a preliminary conclusion in a file acceptance letter is, by its own terms, preliminary — such letters routinely list potential review issues that the review resolves. Neither of those makes the question closed. Both make it genuinely uncertain, which is a different thing from likely to fail.

Form 10-Q — regulatory status and risk factors

04 RRP-001: what 32 open-label patients can and cannot establish

The pivotal evidence is one trial, registered as NCT04398433. Its design deserves to be stated exactly, because the gap between what it measured and what the application asks for is the substance of the regulatory argument.

The results, as the company reports them

• 81.3 per cent (26 of 32) had a decrease in the number of surgical interventions in the year after administration compared with the prior year.
• 28.1 per cent (9 of 32) required no surgical intervention during or after the dosing window.
• Patients had a median of four surgeries in the year before dosing, with an overall range of two to eight; after dosing there was a statistically significant median decrease of three interventions, with a 95 per cent confidence interval of −3 to −2.
• Treatment generated activated CD4 and CD8 T cells with lytic potential, with responses still present at week 52.
• INO-3107 was well tolerated, with mostly Grade 1 treatment-emergent adverse events such as injection-site pain and fatigue.
• Clinical response was not dependent on HPV viral load, molecular subtype or other elements of the papilloma microenvironment.

One point of precision that a careful reader should carry forward: the company presents these figures across shifting denominators — 32 in the original trial, 28 in the retrospective follow-up, 23 described as evaluable in one year-two cut. Each figure is attributable, and this page states the denominator with every number, but the percentages are not comparing identical populations and should not be read as a single clean curve.

The honest summary is that this is a real effect in a disease with a genuine unmet need, measured in a design that cannot prove causation on its own, in a population small enough that a handful of patients moves every percentage. Whether that is enough is precisely what the FDA has reserved judgement on.

ClinicalTrials.gov — RRP-001 (NCT04398433)

05 Durability: what the second and third years showed

The strongest part of the clinical case is not the first year. It is that the effect appears to deepen rather than fade, and that this has now been followed for roughly three years.

In August 2025, data from a retrospective study designated RRP-002 were published in The Laryngoscope. RRP-002 included 28 of the 32 participants from RRP-001 and evaluated them two and three years after initial dosing.

Partial data into the third twelve-month period, at a median follow-up of 2.8 years after initial treatment, continued the trend of improvement and a reduced number of surgeries. The company also notes that only two patients had not responded to treatment by the end of year two.

Two things to hold against that. RRP-002 is retrospective, which means the data were assembled after the fact from patients already known to have been treated, with all the selection and ascertainment problems that implies — and four of the original 32 are not in it. And the comparator is still the pre-treatment year, three years earlier, in a disease whose natural history in an individual patient over three years is not a straight line.

What the durability data do establish, and it matters, is that the first-year result was not a one-off artefact of the baseline surgery. A benefit that holds and grows across three years in the same patients is harder to explain away than a single year’s reduction, and it is the part of the package most likely to carry weight in an argument about meaningful therapeutic benefit.

06 PAPZIMEOS: the approval that changed the standard being applied

In August 2025 PAPZIMEOS, generic name zopapogene imadenovec-drba, was approved for the treatment of adults with recurrent respiratory papillomatosis. It is a gorilla adenoviral vector-based immunotherapy from Precigen, administered as adjuvant treatment following surgical debulking. INOVIO’s filings describe it as a full approval and state flatly that, as a result, the company is at a competitive disadvantage in this indication.

That approval does two separate things to the INO-3107 file, and they should not be conflated.

The regulatory effect

This is the consequential one. An approved therapy for RRP means the disease is no longer one for which there is no available therapy. Accelerated approval therefore requires a showing of benefit over available therapy — a comparative argument, built from a single-arm trial that never enrolled a comparator, against a product approved on its own single-arm trial. The company’s risk factor states the expectation directly: it anticipates the FDA will not approve under the accelerated pathway unless INO-3107 is shown to provide a clinically meaningful benefit over existing therapies, PAPZIMEOS included. The filing also notes that the treatment landscape can change quickly as the FDA converts accelerated approvals to full approvals on the basis of successful confirmatory trials.

The commercial and clinical argument INOVIO makes

The company’s differentiation case rests on the treatment regimen and on a comparison of response rates, both drawn from its own filings:

• Regimen. PAPZIMEOS requires additional surgery prior to its third and fourth doses if visible papilloma are present, in order to maintain a state of minimal residual disease as part of the treatment regimen. INO-3107 requires no additional surgery during the treatment window. For a patient whose entire disease burden is the number of operations they undergo, that is not a small distinction, and it is the heart of what INOVIO calls a patient-centric regimen.
• Response rate. INOVIO states that in a single-arm, open-label Phase 1/2 study of PAPZIMEOS in patients requiring three or more surgical procedures a year, the 24-month complete response rate was 43 per cent. It sets that against its own 50 per cent complete response at the end of year two.

Three cautions on that comparison, which the page states rather than leaves implied. It is INOVIO’s characterisation of a competitor’s data, taken from INOVIO’s filing, not from Precigen’s label or publication. The two trials enrolled different populations under different definitions — the quoted PAPZIMEOS study required three or more procedures a year, RRP-001 required two or more — so the entry severity is not identical. And comparing complete response rates across two separate uncontrolled studies is the weakest form of comparative evidence there is. It is the argument the company is making; it is not proof of superiority, and a regulator assessing meaningful benefit over available therapy will know the difference.

The wider competitive picture is less pressing but worth recording. Merck and GlaxoSmithKline market preventive HPV vaccines, which do not treat established infection; the company notes that even in the United States only an estimated 50 to 60 per cent of the eligible population has been vaccinated. In the cancers and pre-cancers INOVIO targets elsewhere, Advaxis, Genexine and Gilead Sciences have therapeutic candidates in development. None of those bears on October 30.

07 The review timeline and what the tape did with it

This file has a rare property: the regulatory record and the share price record line up closely enough that the market’s reading of each disclosure can be observed rather than guessed at. Prices below are closing prices, independently verified.

Two readings fall out of that table. The first is that the August re-rating was about the review process closing, which means the market had been pricing a meaningful probability of a manufacturing or inspection problem and has now largely stopped. The second is that at $1.22 the shares are still 55 per cent below their twelve-month high and 48 per cent below where they stood a year ago, which is not the price of a market that believes the remaining question is settled.

08 Commercial preparation, and what it would have to carry

The company is preparing for a launch in anticipation of a potential approval in 2026, and the filings name what has been put in place rather than describing it in generalities.

• Syneos Health has been engaged to recruit and deploy Medical Science Liaisons, and is also serving as the contract sales organisation to support commercialisation in the United States.
• The company has engaged or identified a third-party logistics provider, an Agency of Record, a specialty distributor, a specialty pharmacy and a patient HUB.

That is the correct architecture for a rare-disease launch, and the outsourced shape of it is the point. A company with 112 full-time employees as of March 11, 2026, of whom 28 were in general and administrative functions including commercial, cannot build a field force. Renting one from a contract sales organisation converts a fixed cost into a variable one and can be scaled up after a decision rather than before it. The second-quarter accounts show the effect: general and administrative expense actually fell year on year, to $7.8 million in the quarter and $15.7 million over the half from $17.6 million, with the only increase being about $320,000 in the quarter and $308,000 over the half of higher outside services related to commercial development and the planned launch.

So the pre-launch build is real but deliberately thin. Three hundred thousand dollars of incremental commercial spending in a quarter is a company holding its options open, not one committing to a launch.

There is one further structural point, and it is the part of the launch most easily overlooked. INO-3107 is administered by intramuscular injection followed by electroporation with a CELLECTRA device, so a launch requires devices in the field, trained operators and a service model, not just vials. The device that carries a launch is not the one that ran the pivotal trial: the 10-K states that the portfolio consists of the CELLECTRA 5PSP and 3PSP for late-stage and potential commercial use and the CELLECTRA 2000 for earlier-stage trials, that the 5PSP will be used in the planned confirmatory trial for INO-3107, and that although the 5PSP is CE-marked in the European Union the combination product still needs marketing authorisation to be commercialised. The same filings disclose that during the testing required for the BLA submission the company identified a manufacturing issue in the single-use administration component of the 5PSP, which delayed both the confirmatory trial and the BLA; it believes the issue is rectified and says it must still update its existing investigational new drug application with that device alongside the confirmatory trial protocol, subject to further FDA review. Meanwhile device and engineering spending fell 34 per cent over the half, to $6.7 million from $10.1 million. That is a line worth watching after a decision, because a commercial device programme costs more than a clinical one.

09 Financial position at June 30, 2026, and the going-concern statement

All the figures in this section come from the Form 10-Q for the quarter ended June 30, 2026, filed on August 12, 2026, unless stated otherwise.

The income statement, and why the quarterly loss looks small

The second-quarter loss of $6.0 million against $23.5 million a year earlier looks like a transformation and is not one. Operating expenses fell by $4.5 million, which is real; the other $13.0 million of the improvement is a non-cash accounting gain on the revaluation of warrant liabilities, explained in the next section. The line that cannot be flattered is the cash flow: net cash used in operating activities was $39.6 million over the half, against $47.7 million a year earlier. That is the number against which the runway has to be read, and it implies roughly $19.8 million a quarter.

Where the spending went is informative. Research and development fell 19 per cent over the half, but INO-3107 itself went up 6 per cent to $7.9 million. The decline came from engineering and device-related work, down 34 per cent to $6.7 million, other unallocated expenses down 23 per cent to $7.0 million, and immuno-oncology down 34 per cent to $744,000. Stock-based compensation across both expense lines was only $1.4 million for the half. This is a company that has cut everything except the asset in front of the FDA.

The going-concern statement, in the company’s words

Three things follow, and they are arithmetic rather than opinion. Roughly $55 million of resources at the start of the third quarter, against about $19.8 million a quarter of operating cash use, is a little under three quarters — which is what “into late first quarter 2027” means. The guidance explicitly includes a potential launch, so an approval does not relieve the funding need, it brings forward the spending. And a going-concern statement is not a prediction of failure; it is an accounting conclusion that the next twelve months are not funded, which in this case is simply true on the face of the balance sheet.

Two smaller items complete the picture. The investment in Plumbline Life Sciences was written down to zero during the half, a $2.1 million charge, after trading in its shares was suspended on the Korea New Exchange Market and the company determined the market was no longer active. And the stake in Geneos fell from approximately 23 per cent to approximately 9 per cent on an as-converted basis, because Geneos issued preferred equity to third-party investors in the first quarter and INOVIO did not participate. The filing says only that it did not participate, and nothing was charged: the Geneos carrying value had already been written down to zero at both December 31, 2024 and December 31, 2025.

Form 10-Q, quarter ended June 30, 2026

10 The dilution machine, in order

This is the part of the file with the least ambiguity and the most arithmetic. INOVIO has funded itself by selling shares with warrants attached, repeatedly, and at prices that are far below where they started. Every figure below is from a filing.

Read down the price column and the direction is clear but not monotonic: $3.00 combined in December 2024, $1.75 combined in July 2025, $1.90 a share in November 2025, $1.40 combined in April 2026, $0.95 combined in July 2026. The November 2025 deal priced above the one before it, and it is also the only one of the five with no warrants attached.

The warrant column is the more revealing one. December 2024 and November 2025 aside, every offering carried two warrant shares for each share sold: 14,285,715 shares against Series A and Series B each over 14,285,715 in July 2025, and 12,500,000 against two tranches of 12,500,000 in April 2026. July 2026 broke that ratio — warrants over 48.4 million shares against 21.1 million shares sold, more than two for one — at the lowest price of the five and with the strike set at $1.10. Coverage held and then rose while the price fell by almost half, which is not what a company confident of its outcome would accept, and is what a company with a stated going-concern doubt has to accept.

Where the share count has gone

The count has risen 186 per cent in twenty months, and that is after a 1-for-12 reverse stock split implemented in January 2024. The weighted average share count used for earnings per share went from 38,830,053 in the second quarter of 2025 to 81,619,113 in the second quarter of 2026.

The overhang, which is the number that matters most

That structure is worth understanding rather than just fearing, because it cuts in a specific direction. The $1.10 strikes from July 2026 are already in the money and cover 48.4 million shares; the $1.40 strikes cover another 25 million and need a 15 per cent move. An approval that re-rates the shares therefore triggers a wave of warrant exercises that brings in cash — which the company needs — while expanding the count by up to 71 per cent before the $1.75 tranche is even reached. A holder who models an approval without modelling that exercise is modelling half the event.

The reverse case is quieter. Warrants that expire unexercised cost the company nothing and remove the overhang, which is precisely what happened to the July 2025 Series A: 13,564,288 of them, originally set to expire 30 days after the company first publicly disclosed the FDA’s acceptance of the BLA, were amended on January 27, 2026 to extend expiry from January 28 to March 31, 2026, and all of them expired unexercised at a $1.75 strike. Of that series, 721,427 had been exercised earlier for $1.3 million. No warrants from the December 2024 or April 2026 offerings had been exercised at June 30.

The at-the-market programme, currently switched off

The company has a 2024 Equity Distribution Agreement for up to $60.0 million of common stock, with the sales agent entitled to up to 3.0 per cent of gross proceeds. In the first half of 2026 it sold 667,074 shares at a weighted average price of $1.65 for net proceeds of $1.1 million, leaving $56.8 million of capacity at June 30. On April 1, 2026 the company notified the agent that it was suspending and terminating the prospectus related to the agreement, and states that it will make no sales under it unless and until a new prospectus is filed. The agreement itself remains in full force and effect.

So the mechanism is dormant rather than closed, and switching it back on requires a filing rather than a negotiation. A new shelf registration statement on Form S-3, File No. 333-297233, was declared effective on July 10, 2026, and the July offering was made under it. The capacity to raise is in place; only the prospectus is missing.

Form 8-K, July 31, 2026 — underwriting agreement and warrant terms

11 The warrant liability, and why the reported loss halved

A reader looking only at the headline numbers would conclude that INOVIO’s losses are shrinking fast: $23.5 million in the second quarter of 2025 against $6.0 million in the second quarter of 2026. That conclusion would be wrong, and the reason is an accounting mechanic worth ten minutes of anyone’s time because it will distort this company’s reported results in both directions for years.

The warrants issued in December 2024, July 2025 and April 2026 did not meet all the criteria for equity classification and are therefore recorded as liabilities at fair value, remeasured at every balance-sheet date, with the change running through the income statement. The pre-funded warrants issued in April 2024 did meet the criteria and sit in additional paid-in capital.

The consequence is counter-intuitive: when the share price falls, the warrants are worth less, the liability shrinks, and the company books a gain. When the share price rises, the liability grows and the company books a loss.

Strip the warrant revaluation out and the first-half loss is roughly $43.7 million against roughly $45.0 million a year earlier — an improvement of about 3 per cent, not the 41 per cent the headline shows. The cash flow statement confirms it from the other direction: the $18.0 million gain is reversed out as a non-cash item in arriving at the $39.6 million of operating cash use. In the quarter the swing is larger still than it first appears: the warrant line went from a $1.9 million loss a year earlier to a $13.9 million gain, a favourable movement of $15.7 million, partly offset by lower interest income, a higher other-expense charge and the absence of the prior year’s gain on the Plumbline holding.

Two further consequences of the same mechanic deserve stating, because they are easy to get backwards.

An approval would produce a reported loss. If the shares re-rate on a positive decision, the fair value of 97.7 million warrant shares rises sharply and the company books a large non-cash charge. A quarter containing an approval could therefore show a far worse loss than the quarter before it, for reasons that have nothing to do with the business. The reverse also holds: during the first quarter of 2026, when the July 2025 Series A warrants expired unexercised, the remaining liability attached to them was recognised as a gain and the position closed with no further remeasurement.

It is not, however, what distorts the balance-sheet ratios that providers publish. At the September 30, 2026 reading, total debt to equity shows as 1.83 and long-term debt to equity as 1.17, which would suggest a leveraged company. INOVIO has no borrowings. Those two ratios reproduce exactly from the operating lease liabilities alone — $5.1 million non-current over $4.4 million of equity gives 1.17, and adding the $2.9 million current portion gives 1.83 — so the warrant liability is not in them. What makes them meaningless is the denominator: a $4.4 million equity base turns ordinary lease obligations into the appearance of leverage. The current ratio of 1.00 has the same problem in reverse: it looks adequate only because the $25.0 million warrant liability sitting in current liabilities will never be settled in cash.

The honest way to read this balance sheet is to ignore the ratios entirely and look at two numbers: cash of $36.7 million at June 30 plus $18.3 million raised in July, against $19.8 million a quarter of operating cash use.

12 Ownership, short interest and the September 30 session

The market figures in this section are provider fields read on September 30, 2026 and are third-party readings rather than filed numbers. They are reported with that status because none of them can be reconstructed from an SEC document at that date. The price series has been verified independently.

What the short position does and does not say

Nineteen point three per cent of the float short, at 5.29 days of three-month average volume to cover, is a large position by any standard. Two features of this particular case matter more than the headline.

The first is that the cover ratio is low. Five days is not thirteen; this is a liquid stock relative to the size of the short interest, with 3.77 million shares a day of three-month average volume and a float that is effectively the entire share count. A squeeze on good news is mechanically easier here than on a tightly held register, but it is also more quickly exhausted.

The second is that the short case and the warrant structure interact. With 97.7 million shares under warrants at strikes from $1.10 upwards, a short seller can reasonably expect new supply at almost any higher price. That is not a judgement on the drug; it is a structural argument about the share count, and it is available to anyone who reads the warrant table.

Set against that is an aggregated analyst target of $3.17, 160 per cent above the close, with a recommendation score of 1.67 on a one-to-five scale where lower is more positive. Covering analysts and the short base are looking at the same PDUFA date, the same single trial, the same competitor and the same going-concern statement, and reaching opposite conclusions. Neither is adopted on this page. A binary event with a thirty-day fuse is exactly the situation in which professional opinion should be expected to diverge, and the divergence is information about the uncertainty rather than about the answer.

One further note on ownership. Insider ownership of 0.38 per cent is very low, and the provider reports no insider transactions over its window. Twenty-five Forms 4 were filed in 2026, clustered on five dates — February 27, March 5, April 1, May 18 and May 21 — which is the pattern of equity grants and vesting events rather than of scattered market activity. This page has not examined each of them individually and therefore makes no claim about whether any insider has bought or sold in the market; the provider’s insider-transaction field reading 0.00 per cent over its own window is the only summary measure quoted here, and it is a provider field.

13 Retail sentiment

The two readings disagree with each other, and the disagreement is the useful part. The site-facing score of 46 is neutral; the legacy tagged-message split is almost nine to one bullish. The split is calculated only from messages a user chose to tag, which on a ticker like this is a self-selecting population of people who have taken a position and want it known. The canonical score is the signal to quote, and it is unremarkable.

What a reader should take from this block is narrow. A near-unanimous bullish tag count on a stock trading 48 per cent below where it was a year ago, with 19 per cent of its float sold short and an explicit going-concern statement in its last filing, is a description of who is posting rather than of what is happening. Retail discussion ahead of a binary FDA date is overwhelmingly directional by nature; it would be surprising if it were not.

These are comments and scores produced by retail traders who are not professional analysts. They are not clinical evidence, they are not a regulatory fact, and they establish nothing about the probability of an approval on October 30. They are included because a reader who looks at this ticker anywhere else will see them.

StockTwits · $INO

14 Litigation: a trial seventeen days before the PDUFA, and five derivative suits

This section reports what the company has filed about the litigation it is involved in. It takes no view on the merits, which are for a court, and it adopts no allegation.

The VGXI trial, scheduled for October 13, 2026

The first matter in the 10-Q’s list of legal proceedings is not the securities case and it carries the nearer date. On June 3, 2020 the company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, alleging that VGXI materially breached its supply agreement; the complaint seeks declaratory judgments, specific performance, injunctive relief, an accounting, damages, fees, interest and costs. On July 7, 2020 VGXI filed an answer, new matter and counterclaims alleging that INOVIO breached the supply agreement, misappropriated trade secrets and was unjustly enriched, seeking injunctive relief, damages, fees, interest and costs of its own. The company answered on July 27, 2020, disputing the allegations.

The filing then states the thing that matters for the next month: the court has scheduled a seven-day trial to begin on October 13, 2026. The company says it intends to prosecute its claims aggressively and defend the counterclaims. No amount is quantified in the filing, for the claims or the counterclaims, and no accrual appears in the balance sheet.

Two things follow. A six-year-old dispute with a plasmid supplier, with trade-secret counterclaims running against the company, reaches trial seventeen days before the FDA decision. And whatever the verdict, it arrives in the window in which this company has the least financial room it has ever had.

The securities class action

On February 6, 2026 a purported shareholder class action complaint, Carlson v. Inovio Pharmaceuticals, Inc., Jacqueline Shea, and Peter Kies, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the company, its chief executive officer and its chief financial officer as defendants. The lawsuit alleges that the company made materially false and misleading statements regarding its submission to the FDA and the FDA’s review timeline for the INO-3107 Biologics License Application, in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses including attorneys’ fees. On July 27, 2026 the court appointed a lead plaintiff and approved the selection of lead counsel.

The derivative actions

On March 5, 2026 a purported shareholder derivative complaint, Shin v. Shea, et al., was filed in the same court, naming the chief executive officer, the chief financial officer and seven current directors. It asserts state and federal claims based on the same alleged misstatements as the class action, accuses the board of failing to exercise reasonable and prudent supervision over management, policies, internal controls and operations, and seeks unspecified monetary damages on the company’s behalf together with governance reforms.

Three further derivative complaints followed in the same court: Pepito v. Shea on March 16, Panes v. Shea on May 1 and Ghahremani v. Shea on May 27, 2026, asserting substantially similar claims and naming the same defendants. A fifth was filed on July 22, 2026 in a different forum: Andrews v. Shea, in the United States District Court for the District of Delaware, again asserting substantially similar claims to Shin against the same defendants, and therefore outside the consolidation dispute described next, which concerns only the four Pennsylvania actions. The procedural history since is a dispute about who leads them. On March 23 the Shin and Pepito plaintiffs stipulated to consolidation under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation and to the appointment of lead counsel; on May 14 and June 5 the Panes and Ghahremani plaintiffs objected to both. On June 19 the Shin and Pepito plaintiffs filed a notice of non-opposition to that objection, asking the court to defer any decision on consolidation and leadership until after a decision on any motion to dismiss in the class action. All four have stipulated to extend the defendants’ time to respond until the court enters an order on consolidation and a schedule.

What this means in practice, stated carefully

Four observations, each of which can be checked against the filing.

The Pennsylvania derivative cases are parked behind the class action. That is what the procedural manoeuvring amounts to: the plaintiffs themselves have asked the court to wait for a ruling on any motion to dismiss in Carlson before sorting out leadership. The Delaware action sits apart from that arrangement. So the document that matters is the class-action docket, and the first substantive event there is a motion to dismiss.

The subject is disclosure about the review timeline, not the science. No allegation reported in the filing concerns the trial data, the manufacturing or the product. The allegation is about what the company told the market concerning its submission and the FDA’s review timeline — which places the December 2025 acceptance announcement, the standard rather than priority review class and the eligibility comment in the file acceptance letter at the centre of the case.

No provision appears in the accounts, for any of it. The company states that it assesses contingencies and accrues an estimated loss where a liability is probable and the amount reasonably estimable. No accrual for the securities matters or for the VGXI counterclaims is reported in the second-quarter balance sheet, which is the ordinary treatment at this stage and not an indication of how the cases will resolve.

Management concluded the controls were effective anyway. The disclosure controls evaluation states that in reaching its conclusion that controls were effective as of June 30, 2026, management considered the pending class action and derivative complaints and determined that the litigation did not affect that effectiveness. That is a disclosed judgement by management about its own controls, recorded here as such.

The cost side is visible in the accounts, though in the opposite direction from what one might expect. General and administrative expense fell year on year partly because of $902,000 in lower legal expenses in the quarter and $1.2 million over the half, attributed to a decrease in litigation activity. That refers to the overall legal load rather than to these cases specifically, and it is a reminder that this company was already carrying litigation before February 2026 — the VGXI matter has been running since 2020.

Form 10-Q, Note 10 and Part II Item 1 — legal proceedings

15 Management, governance and what the execution record shows

INOVIO is led by Dr Jacqueline Shea as President and Chief Executive Officer, with Peter Kies as Chief Financial Officer. The company employed 112 people on a full-time basis as of March 11, 2026 — 84 in product research, which covers research and development, quality assurance, clinical, engineering and manufacturing, and 28 in general and administrative functions including corporate development, information technology, legal, commercial, investor relations, finance and corporate administration. Approximately half the workforce is women. The company was incorporated in Delaware in May 2001 and is based in Plymouth Meeting, Pennsylvania. As of March 11, 2026 it had approximately 215 common stockholders of record, which reflects street-name holding rather than the real shareholder base.

Governance changes in 2026

On May 19, 2026 the board approved an amendment to the bylaws, effective immediately, which among other things clarified the role of the Chairman of the Board, including that the Chairman is not deemed an officer unless expressly designated as such; established the position of Lead Independent Director with its designation, duties and responsibilities; required the appointment of a Lead Independent Director whenever the chief executive officer also serves as Chairman; and updated the order of presiding officers at meetings. The company describes this as further enhancing its corporate governance practices.

The timing invites a question and the filing does not answer it. The amendment came ten weeks after the first derivative complaint accused the board of failing to supervise management, and derivative plaintiffs in such cases typically seek governance reforms as part of their relief. Whether the two are connected is not stated in any document reviewed for this page, and this page will not assert a link it cannot source. What can be said is that creating a Lead Independent Director position is a substantive change and a conventional response to exactly the criticism being made.

At the annual meeting held on May 20, 2026, 40,670,629 shares, or 58.57 per cent of the 69,438,100 entitled to vote as of the record date — a figure which includes shares issuable on conversion of the outstanding Series C Cumulative Convertible Preferred — were present or represented. Eight directors were elected.

Execution, split into what is demonstrated and what is not

Demonstrated. The company completed and filed a BLA, had it accepted, and brought it through mid-cycle and late-cycle review and all scheduled pre-licensure inspections without a disclosed observation. It published the pivotal results in Nature Communications and the durability follow-up in The Laryngoscope. It secured Orphan Drug and Breakthrough Therapy designations, a European orphan designation, UK ILAP status and an EMA Committee for Advanced Therapies certification of its quality and non-clinical data. It cut operating expenses 16 per cent over the half while increasing spending on the lead asset. And it has funded itself continuously through a period in which its share price fell by half.

Not demonstrated. The company has never sold a product; total revenue in the first half of 2026 was zero. It requested a priority review and received a standard one. It did not obtain a resolution of the eligibility question in the seven and a half months between the file acceptance letter and the last filing, and the July meeting ended without the agency revisiting the point. It states it is not planning for the traditional pathway. It has had to accept progressively worse financing terms as the catalyst approached. And it is defending a securities class action about the adequacy of its own disclosures on precisely the regulatory timeline that this page spends most of its length on.

The fair summary is of a small team executing competently on the mechanics of a regulatory filing while being unable to control either the question the agency has reserved or the price at which it must raise money. Those are different kinds of failure and only the second is a management failure — but the second is the one that determines what a shareholder owns on the other side of October 30.

16 The rest of the pipeline, and what the company is trying to partner away

Almost all of INOVIO’s value rests on INO-3107, and the filings are explicit that the majority of resources are focused there. The rest of the pipeline is useful mainly as a map of what the company would still own after October 30, and the most informative division in it is between what INOVIO develops itself and what it is looking for a partner to pay for.

The platform, in one paragraph

INOVIO designs DNA plasmids — small circular DNA molecules which the company describes as working like software that the body’s cells can download to produce specific proteins. Delivery is by its proprietary investigational CELLECTRA devices, which it says achieve the effect without chemical adjuvants, lipid nanoparticles or viral vectors. That last clause is the platform’s differentiation claim, and the approved competitor in RRP is a viral-vector product.

What the company is advancing

• INO-3112 for HPV-related oropharyngeal squamous cell carcinoma: two plasmids targeting HPV-16 and HPV-18 E6 and E7 antigens plus an IL-12 plasmid. A Phase 1b/2a trial in combination with AstraZeneca’s durvalumab, published in Clinical Cancer Research in early 2023, reported an objective response rate of 27.6 per cent with four complete and four partial responses in 29 evaluable patients, and a median overall survival of more than 29 months. The company has a clinical collaboration and supply agreement with Coherus BioSciences, under which Coherus provides LOQTORZI for a planned Phase 3 trial, and states it has gained alignment with the FDA on that trial’s design and received initial feedback from European regulators. Planned is the operative word: no Phase 3 has started.
• INO-5412 in glioblastoma: INO-5401 and INO-9012 combined in a single vial, being evaluated with Akeso’s PD-1/CTLA-4 bispecific checkpoint inhibitor in a Phase 2 adaptive platform trial sponsored by the Dana-Farber Cancer Institute, announced in early 2026. INO-5401 encodes the company’s SynCon antigens for hTERT, WT1 and PSMA; INO-9012 encodes IL-12. The structure matters: the trial is sponsored by Dana-Farber and the checkpoint inhibitor comes from Akeso, so INOVIO contributes material rather than funding.
• VGX-3100 in anal and perianal high-grade squamous intraepithelial lesions, where a Phase 2 trial sponsored by the AIDS Malignancy Consortium is evaluating it in HIV-positive patients. Again sponsored by a third party.
• Other programmes targeting cancers associated with certain gene mutations and an Ebola vaccine booster.

What the company is seeking partners for

The 10-Q states that the company is working to identify partnership opportunities to advance its DNA-Encoded Protein and DNA-Encoded Monoclonal Antibody technologies, with a focus on developing additional DPROT indications in the rare disease space, including Fabry disease and hypophosphatasia. A platform looking for a partner is a platform the company cannot fund, and that is the honest reading of a line in a filing that also carries a going-concern statement.

The discontinued asset that produced good news anyway

INOVIO stopped developing VGX-3100 for cervical high-grade squamous intraepithelial lesions in the United States in 2023, after the second Phase 3 trial failed to achieve statistical significance in the biomarker-selected population for lesion regression and viral clearance, although it did achieve it in the all-participants population. Its collaborator ApolloBio has continued a Phase 3 trial in China and announced positive topline results in May 2026; ApolloBio plans to use those results to seek regulatory approval and, if approved, to commercialise the candidate in that jurisdiction. The economics of that to INOVIO are not quantified in the filings reviewed here, and the only revenue the company has recorded from the ApolloBio arrangement in the periods shown is $65,343 in the first half of 2025 and nothing in 2026.

One write-down and one dilution complete the picture. The investment in Plumbline Life Sciences was marked to zero in the first half of 2026, a $2.1 million charge, after trading in its shares was suspended in Korea. The stake in Geneos fell from approximately 23 per cent to approximately 9 per cent on an as-converted basis, because Geneos raised preferred equity from third parties in the first quarter and INOVIO did not participate — and that one cost nothing in the accounts, because the Geneos carrying value had already been reduced to zero at both December 31, 2024 and December 31, 2025. The company adds that notwithstanding the fall below 20 per cent it determined it retains the ability to exercise significant influence over Geneos, holding a board seat through its chief scientific officer, participating in scientific and strategic decisions and maintaining an exclusive licensing relationship, and continues to account for the holding under the equity method.

The company’s stated partners and collaborators are Akeso, ApolloBio, AstraZeneca, Coherus Biosciences, Dana-Farber Cancer Institute, DARPA, the HIV Vaccines Trial Network, Kaneka Eurogentec, the NIH, NIAID, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania and The Wistar Institute. It is a long list for a company of 112 people, and it reflects a platform that has been licensed and collaborated on widely while generating almost no revenue from any of it.

17 Catalyst map

The structural point is that this file has two dated events seventeen days apart and then a funding problem. Unlike a company with a portfolio of readouts, INOVIO has arranged almost everything behind the October 30 decision, and the balance sheet was sized to reach that date rather than to absorb its outcome.

18 Red flags

Each of these is drawn from a filing or a registry record, not from commentary.

• The FDA has questioned eligibility for the pathway in writing, and the question was still open at the last filing. The December 2025 file acceptance letter noted as a potential review issue the agency’s preliminary conclusion that the company had not provided adequate information to justify eligibility for accelerated approval. At the July 2026 meeting the FDA did not discuss that commentary. The 10-Q concedes the agency may decide INO-3107 is not eligible.
• There is no stated alternative route. The company says it is not currently planning to seek approval under the traditional pathway, which could potentially require a Phase 3 trial agreed with the FDA at substantial cost — a trial a company with $36.7 million at June 30 and a going-concern doubt could not fund as it stands.
• Substantial doubt about the going concern, in the company’s own words. Management believes there is substantial doubt about the ability to continue as a going concern beyond the first quarter of 2027, and the risk factors state the company does not currently have sufficient working capital to fund planned operations for the next twelve months. Working capital at June 30 was negative $2,000 and total equity $4.4 million.
• An approved competitor holds the ground. PAPZIMEOS was approved for adults with RRP in August 2025. The company states that as a result it is at a competitive disadvantage in this indication, and that it anticipates the FDA will not approve under the accelerated pathway unless INO-3107 is shown to be clinically meaningfully better than existing therapies including PAPZIMEOS.
• The evidence base is a 32-patient single-arm trial whose primary endpoint was safety. RRP-001 had no control group; the surgical-reduction result everyone quotes is a secondary outcome, measured against each patient’s own prior year, in a population selected for having had at least two operations in that year.
• Dilution with a documented pattern, at falling prices. Shares outstanding went from 36,099,991 at the end of 2024 to 103,397,518 by August 10, 2026, after a 1-for-12 reverse split in January 2024. Successive unit offerings priced at $1.90, then $1.40, then $0.95, with the warrant coverage rising each time.
• 97,706,767 shares under warrants, 94.5 per cent of the current count, at strikes of $1.10, $1.40, $1.75 and $3.76 against a $1.22 close. An approval that re-rates the shares converts much of that overhang into new supply.
• A securities class action and five derivative suits, about disclosure of the review timeline. A lead plaintiff was appointed in Carlson v. Inovio on July 27, 2026, and the five derivative actions — four in the Eastern District of Pennsylvania and one in the District of Delaware — name the chief executive, the chief financial officer and seven directors.
• A seven-day trial in the VGXI supply dispute begins on October 13, 2026, seventeen days before the PDUFA date, with trade-secret and breach counterclaims running against the company. No amount is quantified and no accrual appears in the accounts.
• A manufacturing issue on the device, disclosed and said to be rectified. During the testing required for the BLA submission the company identified a manufacturing issue in the single-use administration component of its CELLECTRA 5PSP device, which it says delayed both the confirmatory trial and the BLA. It must also update its existing investigational new drug application with the 5PSP device alongside the confirmatory trial protocol, which will be subject to further FDA review.
• Reported losses are distorted by warrant revaluation in both directions. The second-quarter loss of $6.0 million includes a $13.9 million non-cash gain from the share price falling. On the same mechanic, a quarter containing an approval would show a far larger reported loss.
• No revenue, and no disclosed price. Total revenue was zero for the first half of 2026. No list price or wholesale acquisition cost for INO-3107 appears in the filings reviewed here.
• A thirty-year-old prevalence estimate underpins the market size. The company cites 1995 United States epidemiology estimating approximately 14,000 active adult and juvenile cases.
• Insiders own 0.38 per cent and are not buying. The provider reports no insider transactions over its window, and the only 2026 Forms 4 are dated May 21, consistent with annual grants rather than market purchases.

19 What to watch on and after October 30

A reader who wants to follow this rather than react to it should watch documents in a specific order, because each one answers a different question.

The decision itself, and its wording. An approval under the accelerated approval program answers the eligibility question and creates a confirmatory trial obligation. A complete response letter, if one arrives, will state what the agency wants — and whether that is a comparative trial, more data on eligibility, or something procedural is the whole difference between a delay and a different company.

The confirmatory trial design. If approval comes, this is the number that determines the financing. The FDA said at the July meeting that feedback on the design would be forthcoming; the company has not disclosed a size, a duration or a cost. A comparative confirmatory trial in a rare disease with an approved competitor is not a small undertaking, and it would be a commitment made by a company whose stated runway ends in late first quarter 2027.

The price, and the first shipment. No list price has been disclosed. In a disease measured in thousands of patients, the price is the business, and it will appear either in a company announcement or in the first quarter that carries a revenue line.

The financing, and its terms. This is the one item that is close to certain in either outcome. Watch whether it is an at-the-market restart, which requires only a new prospectus against $56.8 million of capacity, or another structured unit deal with warrants attached. The former signals a company selling into strength; the latter signals one taking what it can get. The last three deals were all the latter.

The share count and the warrant table. Both appear in every quarterly filing. On an approval, watch how quickly the $1.10 and $1.40 strikes are exercised: it brings in cash and expands the count at the same time.

The VGXI verdict, and then the class-action docket. The seven-day trial begins on October 13, seventeen days before the decision, and nothing in the filings quantifies what is at stake in either direction. After that, a motion to dismiss in Carlson is the next substantive event, and the four Pennsylvania derivative plaintiffs have asked the court to wait for it.

What not to watch: tagged-message sentiment counts, aggregated price targets and any date for a European or Japanese filing, because no such application is disclosed in any document reviewed for this page.

20 Merlintrader bottom line

INOVIO has spent twenty-five years accumulating a deficit of $1,840.9 million against paid-in capital of $1,845.4 million, and it has arrived at a dated decision with $4.4 million of book equity left. That sentence is not editorial colour; it is the balance sheet at June 30, 2026 next to the additional paid-in capital line.

What the company has done well is narrow and real. The clinical signal in recurrent respiratory papillomatosis is one of the more concrete things in rare disease: patients who were having a median of four operations a year had three fewer, and three years on half of the evaluable group needed none at all, with no serious adverse events identified over that period. The application was assembled, accepted, taken through mid-cycle and late-cycle review and through every scheduled pre-licensure inspection without a disclosed problem. For a company of 112 people with a device as part of its product, that is competent regulatory execution, and the market recognised it: the shares went from $0.77 to $1.30 in the five sessions after the August 12 filing disclosed it.

What has not been resolved is the thing the company cannot resolve on its own. The FDA wrote, when it accepted the application, that in its preliminary view the company had not justified eligibility for the accelerated approval pathway. Around seven months later, at the informal meeting the company had asked for, the agency did not revisit the point. In between, a competitor took a full approval in the same disease, which removes the simpler of the two statutory routes and leaves a comparative argument that must be built from a 32-patient uncontrolled study whose registered primary endpoint was safety. The company says it is not planning for the traditional pathway. So the structure of the file is that one route is contested and the other is not funded.

The financial side is easier to state and harder to look at. Cash, equivalents and investments of $36.7 million at June 30, plus roughly $18.3 million raised in July at a combined $0.95 with more than two warrant shares attached per share sold, against operating cash use running at about $19.8 million a quarter. Guidance runs into late first quarter 2027, explicitly including a potential launch, and the filing states substantial doubt about the going concern beyond it. Shares outstanding have gone from 36.1 million to 103.4 million in twenty months, after a reverse split, and 97.7 million more sit under warrants at strikes starting below the current price. Whatever happens on October 30, a financing follows within months; the only question the decision settles is at what price.

Two further things sit inside the same month and are easy to lose behind the PDUFA date. A seven-day trial in the VGXI supply dispute, with trade-secret counterclaims against the company, begins on October 13, unquantified in the filings and unaccrued in the accounts. And the device that would carry a launch is not the one used in the pivotal trial: the CELLECTRA 5PSP had a manufacturing issue in its single-use administration component that the company says delayed both the BLA and the confirmatory trial, and the investigational new drug application still has to be updated with that device, subject to further FDA review.

The symmetry a reader should hold onto is this. An approval does not end the funding problem, it accelerates the spending and converts the warrant overhang into supply. A refusal does not end the company, but it leaves a pathway the company says it is not planning for, at a cost it would have to raise for at a much lower price. Those two outcomes are not mirror images, and the sell side’s $3.17 aggregate target and the 19.3 per cent short position are both defensible readings of the same filings.

This is editorial research for informational purposes. It is not advice, not a recommendation, and it takes no view on whether the shares are worth their price or on what the FDA will decide.